Climate change poses a fundamental threat to our livelihood and addressing the crisis through the reduction of carbon pollution is vital. The National Health Service (NHS) in the UK has committed to reducing the carbon footprint from inhaler devices by 50% by 2030, primarily through a reduction in the use of pressurised metered-dose inhalers (pMDI). The development of pMDIs utilising lower global warming potential propellants by 2025 is currently underway. This article focuses on the need to apply an individualised approach for patient outcomes whilst minimising the carbon footprint of their inhaler treatments.

This article highlights a poster presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® Digital Experience congress and summarises a symposium session from the North American Society for Pediatric Gastroenterology…